Author:
Bai Long,Wang Feng,Zhang Dong-sheng,Li Cong,Jin Ying,Wang De-shen,Chen Dong-liang,Qiu Miao-zhen,Luo Hui-yan,Wang Zhi-qiang,Li Yu-hong,Wang Feng-hua,Xu Rui-hua
Publisher
Springer Science and Business Media LLC
Reference63 articles.
1. Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8, 579 (2008).
2. Strickler, J. H. & Hurwitz, H. I. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist 17, 513 (2012).
3. Guan, Z. Z. et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 30, 682 (2011).
4. Bai, L. et al. Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment. Med Oncol 32, 469 (2015).
5. Macedo, L. T., Da, C. L. A. & Sasse, A. D. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. Bmc Cancer 12, 89 (2012).
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献